Medtronic's Infuse Tied To Male Infertility Risks

Law360, New York (May 25, 2011, 7:16 PM EDT) -- A medical study released Wednesday suggested that the use of Medtronic Inc.'s popular bone growth product Infuse in some spine surgeries may increase the risk of male infertility.

Eugene J. Carragee of the Stanford School of Medicine, the lead author of the study published in The Spine Journal, said in a statement that while male infertility has long been a known risk in some spine surgeries, spinal fusion procedures using rhBMP-2 — a manufactured protein and the active ingredient in Infuse — appears to be greater...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.